Coave Therapeutics
PrivateLast Round
Series A
Jan 9, 2025
Total Funding Raised
$131.4M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Coave Therapeutics is a biotechnology company that develops targeted gene therapies for rare ocular and central nervous system (CNS) diseases using its proprietary ALIGATER™ platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Coave Therapeutics Comparables
Compare Coave Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Capsida Biotherapeutics | 84% | |
| AviadoBio | 79% | |
| Atsena Therapeutics | 78% |
Coave Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 9, 2025 | ||||
| Series A | Jan 9, 2025 | ||||
| Series B | Jul 21, 2021 | ||||
| Series B | Nov 8, 2017 | ||||
| Series A | Jul 8, 2016 |
Coave Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fund+ | Series B, Series A |
| Seroba Life Sciences | Series A, Series B |
| Pontifax Venture Capital | Series B |
| Turenne Groupe | Series B, Series A |
| Eurazeo Investment Manager | Series B |
| V-Bio Ventures | Series B |
| GO Capital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 7, 2.6x the trailing average.
- Oct 7, 2025
Demonstrated novel suprachoroidal capsid technology at ESGCT Congress 2025.
Recent news
Latest coverage and updates
- attends_eventSep 24, 2026
Coave Therapeutics SA will attend event 26th Euretina Congress on Oct 4th '26.
- attends_eventSep 24, 2026
Coave Therapeutics SA will attend event Euretina Innovation Spotlight (EIS) conference on Sep 30th '26.
- hiresSep 16, 2026
Coave Therapeutics SA hires Nora Dimon.
Coave Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Coave Therapeutics's valuation, stock price, and market status.
Is Coave Therapeutics a public or private company?
Coave Therapeutics is a private company.
What is the current stock price of Coave Therapeutics?
Coave Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Coave Therapeutics worth (valuation)?
Valuation information for Coave Therapeutics is not publicly available.
Can I buy Coave Therapeutics stock?
Coave Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Coave Therapeutics's last funding round?
Coave Therapeutics's most recent funding round was Series A on January 9, 2025.
Who are the main investors in Coave Therapeutics?
Key investors in Coave Therapeutics include Seroba Life Sciences, Bpifrance, Novo Holdings, Bpifrance, Kurma Partners.
Will Coave Therapeutics IPO soon?
No public IPO plans have been announced for Coave Therapeutics.
How can I track Coave Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Coave Therapeutics's secondary market activity and sign up for updates.